表紙
市場調査レポート

医薬品のブラジル市場展望:2015-2025年

Brazilian Pharmaceutical Market Outlook 2015-2025

発行 Visiongain Ltd 商品コード 290179
出版日 ページ情報 英文 199 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.53円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品のブラジル市場展望:2015-2025年 Brazilian Pharmaceutical Market Outlook 2015-2025
出版日: 2015年02月18日 ページ情報: 英文 199 Pages
概要

ブラジルの医薬品市場は2019年に506億米ドルに達すると予測されています。

当レポートは、ブラジルの医薬品市場について調査し、国レベル・2次市場における収益の予測、国内・海外のディベロッパー・メーカー・販売業者の見通し、および市場の促進因子・阻害因子の分析などをまとめ、お届けいたします。

第1章 調査概要

第2章 ブラジルの医薬品市場:イントロダクション

  • ブラジルの医薬品市場概要
  • ジェネリック医薬品区分は引き続き重要性を増す
  • CNS (中枢神経系) は最大の治療領域
  • 国内企業4社がトップ10に

第3章 ブラジル市場が問題な理由:世界的な市場背景

  • 2014年における世界第7位の経済国:2023年までに第5位に
  • 2013年における世界第6位の医薬品市場:2016年までに第4位に
  • 2014年においてラテンアメリカの医薬品市場の40%をブラジルが占める
  • ブラジルは医薬品新興国市場 (Pharmerging) およびBRIC市場の一部

第4章 ブラジル医薬品市場の組織

  • ANVISA:主要な団体
  • Sindusfarma および ABRAFARMA などの重要な機関
  • 26%の国民が民間の医療保険で SUS (統一保健医療システム) を補完
  • CMED (医薬品販売規制審議会) は3.35%の平均薬価上昇を発表
  • リネーム医薬品および薬局 (Farmacia) が人気
  • 民間保健市場の成長、しかし保険業者のコストは上昇
  • M&A主導の統合がホールセール・小売り部門で続く
  • ブラジルにおけるマーケティング支出は50億米ドルに近付く:医薬品広告に対する新たな規定

第5章 ブラジルの地域間で多様な医療

  • 人口、医薬品市場のシェアおよびGDP:地域別
  • 南東部:人口の42%、医薬品収益の53%
  • 南部:最も小さい地域、しかし二番目に高いGDP
  • 北東部:2番目に高い医薬品市場シェア、しかし国民1人あたりのGDPは最も低い
  • 北部:最も大きく最も貧しい地域、医薬品市場の5%以下
  • 中西部:首都を抱える内陸地域、人口は最も少ない

第6章 ブラジルの医薬品市場の内訳:製品別

  • 市場の特許処方薬、ジェネリック医薬品およびOTC区分の予測
  • 特許処方薬の予測
  • ジェネリック医薬品区分の予測
  • ブラジルの生物製剤市場
  • OTC区分の予測

第7章 ブラジル市場における治療領域

  • CNS、心血管、消化管/代謝、がん、感染症およびその他の治療領域
  • 非伝染性疾病の増加
  • CNS疾患市場の予測
  • 心血管治療領域の市場予測
  • 消化管/代謝治療領域の予測
  • がん治療薬市場の予測
  • 感染症治療領域の予測
  • その他の治療領域

第8章 ブラジル市場における国内企業

第9章 ブラジル市場における多国籍企業

第10章 ブラジルの医薬品市場の定性分析

  • ブラジルにおける医薬品企業の上位10社
  • 2009年におけるMedleyの買収は多国籍企業が依然として市場の大部分を支配していることを意味
  • 国内企業がジェネリック医薬品市場の70%を支配
  • EMS:ブラジル最大の医薬品企業
  • Hypermarcas
  • Medley
  • Ache
  • Eurofarma
  • Teuto
  • Biolab Farmaceutica
  • Cristali
  • Libbs
  • Uniao Quimica
  • Moksha8 および Laboratorio Daudt Oliveiraなど、その他の国内企業
  • バイオシミラーとのコラボレーション
  • Biomm および Innovaなど、その他のバイオテクノロジー企業
  • Fiocruz
  • ブラジルの特許制度によるANVISAの改革

第11章 調査インタビュー

第12章 調査・分析の結論

  • ブラジルはその他のトップ10医薬品市場より速く成長する見込み
  • ジェネリック医薬品は最も急成長する区分となる見込み
  • 技術移転は特許医薬品市場にとって重要
  • ジェネリック医薬品:多国籍企業にとっての機会?
  • がん治療:最大の治療・商業機会
  • 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0030

Medicine sales in Brazil - your guide to trends, opportunities and revenue prospects

Do you want to assess Brazil's pharmaceutical sales from 2015? See what lies ahead. Visiongain's new study gives you multilevel revenue forecasts, helping your research and analysis. That report's purpose is showing results, opportunities and future business trends.

Brazil can satisfy expectations for expanding healthcare coverage and rapid growth of its drugs market. Discover what's possible, to 2025, for pharma companies operating in that developing country. You find business analysis, developments and potential revenues.

So please read on to explore Brazilian medical sales and discover how high that market's revenues could go.

Trends and outlooks for that emerging healthcare market - what's possible?

Our study covers small molecule medicines and biological drugs (biologics), including biosimilars and vaccines. From 2015 patients, healthcare providers and the pharmaceutical industry will benefit from medical progress in Brazil. You discover where, how and why.

That updated work lets you find business predictions from 2015 to 2025 at overall national and submarket levels. You discover the most lucrative parts of that market, seeing what the future holds for pharma revenue generation.

And you discover trends and analyses explaining existing and expected progress.

Forecasts and other data helping you find where the money lies in Brazil's medical sales

To support our forecasting, our work shows you historical data, recent results, growth rates and market shares. There you investigate developments and potentials, finding what they mean and their values. You also get 53 tables, 58 charts and an exclusive interview.

Also save time and avoid struggles to find data for your research, analysis and planning. See, too, how you can help your influence, benefiting your reputation for commercial insight.

And the following sections highlight analyses our new investigation gives.

Potentials of Brazilian medical business - forecasting of that overall market and its segments

What's Brazil's potential? What're the secrets of that country's expansion of pharma sales?

There discover overall drug revenues to 2025, with discussions. Our report then shows individual sales predictions - from 2015 to 2025 - for six main submarkets:

  • Patented therapies - original brands of prescription pharmaceuticals, also with prediction of vaccine and biological drug (grouped) revenues
  • Generic drugs (prescription generics), also with grouped forecasting of biosimilar revenues
  • OTC medicines - over-the-counter products.

The author of that report said: "The future looks promising for Brazilian pharmaceutical sales. That emerging national market is growing at a much faster rate than more mature markets, such as the US and the EU5, and will continue to do so over the next ten years."

Hear what's possible, then, getting a feel for that country's medical needs and pharma business. Also gain forecasting of therapeutic applications, via separate analyses.

Diseases and their treatment - what prospects for drugs and their sellers?

The updated study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2025 for six therapeutic categories:

  • Central nervous system (CNS) products
  • Cardiovascular (CV) treatments
  • Alimentary and metabolic disorders therapy
  • Cancer treatments (oncology)
  • Infectious diseases - anti-infective agents (vaccines and antibiotics)
  • Therapies for other illnesses (grouped).

How fast will those submarkets expand? And which treatment classes will give highest revenues? There you assess opportunities and potentials, seeing where you can gain.

You also investigate what stimulates and restrains sales of pharmaceuticals there.

Issues and events in Brazil - what affects drug developers, producers and sellers?

Our report also discusses forces influencing sales of medicines there from 2015 to 2025, including these forces:

  • Strategies companies and public healthcare providers use to serve patients' needs
  • Efforts of domestic and foreign companies, inc. mergers and acquisitions (M&A activity), drug launches, sales ranking and Brazilian market share
  • Trends in demographics, economics and epidemiology - assess rising medical needs and how to serve them
  • Wholesalers, distributors and retailers of medicines - the supply chain
  • Governmental policies, inc. pricing and reimbursement and other regulations.

And assess these influences, among others:

  • Efforts by regions to improve medical provision, better serving populations
  • Healthcare insurance - public and private - to benefit patients
  • Technologies - competitors' research and development (R&D) and manufacturing
  • Technology transfer and IP protection, including action against counterfeiting
  • Rising demand for biological drugs, including biosimilars (follow-on protein products)
  • Brazil's position in overall world, Latin American, BRIC nations and pharmerging countries' pharma activity.

There you examine political, economic, social and technological questions, assessing commercial outlooks. And also strengths, weaknesses, opportunities and threats. Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil.

Analysis of top companies and their industry's performance - what future sales possible?

What happens next? Our work predicts the Brazilian pharma market will reach $50.6bn in 2019 - with strong expansion. By 2025 it can become one of the world's big drug markets.

You discover what causes that progress and what's possible. Our study explains activities of 10 leading domestic companies, in particular, including these firms:

  • EMS
  • Hypermarcas
  • Aché
  • Eurofarma
  • Cristália
  • Libbs
  • União Química.

You also see activities of 10 multinational (big pharma) organisations and other foreign players, including these corporations:

  • Sanofi
  • Novartis
  • Roche
  • Merck & Co.
  • Pfizer
  • Takeda
  • Bayer.

You also see an interview with BiocadBrazil Farmaceutica. Discover the efforts of specialists, including firms making biopharmaceuticals.

Developments of leading generics and biosimilar producers and sellers

In that report you also see international manufacturers and marketers of generic drugs and biosimilars targeting Brazil, including these companies:

  • Teva Pharmaceutical Industries
  • Mylan
  • Actavis
  • Glenmark
  • Valeant
  • Glenmark
  • Strides Arcolab
  • Biocon.

From 2015 great progress in Brazilian medical sales will occur. Pharma industry leaders and specialty operations - esp. manufacturers of generic and biosimilar drugs - stand to benefit. See, then, what's possible and how you can gain.

Ways Brazilian Pharmaceutical Market Outlook 2015-2025 helps your work

In these five main ways, our investigation gives knowledge to help your research, analyses and decisions:

  • Brazil's overall pharma revenues from 2015 - discover that top developing country's prospects for investments, marketing and sales
  • Submarkets' revenues to 2025 - investigate 12 segments at national level, finding product groups and therapeutic needs with highest potential revenues
  • Prospects for domestic and foreign drug developers, producers and sellers - explore portfolios, R&D, approvals, collaborations, M&A and outlooks
  • Opinion and news from companies - see views to help you stay ahead
  • Analysis of what stimulates and restrains Brazil's drugs market - assess challenges and strengths there, helping you compete and gain advantages.

Those analyses help you avoid falling behind, giving predictions top companies depend on again and again.

Information found nowhere else, showing you the potential of Brazil's pharma sales

Our report gives independent analysis. There you receive business intelligence found only in our work, finding where the money lies. Discover progress and possibilities.

With that study you're more likely to stay ahead in knowledge and find opportunity. Through choosing our survey you see how you could save time and effort, also benefiting your authority and influence.

Predictions for medical businesses there - discover what results are possible

Our new investigation is for everyone analysing emerging pharma markets. Brazil holds great potential - see what's possible. So avoid missing out.

Table of Contents

1. Report Overview

  • 1.1 Brazil's Pharma Market: Overview
  • 1.2 Brazilian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Main Questions Answered by This Study
  • 1.6 Who is This Investigation For?
  • 1.7 Research and Analysis Methods
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Some Associated Reports
  • 1.10 About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market, 2015-2025

  • 2.1 The Brazilian Pharmaceutical Market Overview
  • 2.2 Generics Segment Continues to Grow in Importance
  • 2.3 CNS the Largest Therapeutic Area in 2014
  • 2.4 Four Domestic Companies in the Top Ten in 2014

3. Why the Brazilian Market Matters: Global Market Context

  • 3.1 Seventh-Largest Global Economy in 2014. Fifth-Largest by 2023
  • 3.2 Sixth-Largest Pharmaceutical Market in the World in 2013. Fourth-Largest by 2016
  • 3.3 Brazil Represented 40% of the Latin American Pharmaceutical Market in 2014
  • 3.4 Brazil as Part of the Pharmerging and BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market

  • 4.1 ANVISA: The Key Institutional Body
  • 4.2 Important Agencies Include Sindusfarma and ABRAFARMA
  • 4.3 26% Supplement SUS with Private Healthcare in 2014
  • 4.4 CMED Announces Average Drug Price Increase of 3.35%
  • 4.5 RENAME Drugs and the Farmácia Popular
  • 4.6 Private Insurance Market Growing, but Costs for Insurers Rising
  • 4.7 M&A Led Consolidation Continues in Wholesale and Retail Sectors
    • 4.7.1 Celesio-Owned Panpharma Still the Top Distributor
    • 4.7.2 2013 Acquisition Makes Profarma the Largest Mixed Distributor
    • 4.7.3 Raia Drogasil, DPSP SA and Brasil Pharma are the Leading Companies in the Retail Sector
  • 4.8 Marketing Spend in Brazil Approaches $5bn; New Rules on Drug Advertising

5. Healthcare Variations between the Brazilian Regions

  • 5.1 Population, Pharmaceutical Market Share and GDP by Region
  • 5.2 South East: 42% of the National Population and 53% of Pharmaceutical Market Revenues
  • 5.3 South: The Smallest Region, but Second-Highest GDP
  • 5.4 North East: Second-Highest Pharmaceutical Market Share but Lowest Per Capita GDP
  • 5.5 North: Largest and Poorest Region, Represents Less Than 5% of the Pharmaceutical Market
  • 5.6 Midwest: Landlocked Region with the Nation's Capital and the Lowest Population

6. Breakdown of the Brazilian Pharmaceutical Market by Product Type, 2015-2025

  • 6.1 Forecasts for the Patented Prescription, Generic and OTC Segments of the Market, 2015-2025
  • 6.2 Patented Prescription Drugs Forecast - Dominant Segment of the Market, But for How Much Longer?
    • 6.2.1 PDPs: a Flagship Programme by the MoH for Bringing Down Costs
    • 6.2.2 At 55% More Expensive, Patented Products are Struggling to Hold off the Generics Revolution
  • 6.3 Generic Drugs Segment Forecast 2015-2025 - Continued Rapid Growth
    • 6.3.1 Generic Pharmaceuticals: Rapid Expansion Since 2000
    • 6.3.2 Pró-Genéricos Anticipate 45% Market Capture
    • 6.3.3 Similares Drugs and Patient Confidence in Generics
    • 6.3.4 Counterfeits: 7-22% of Drugs in Latin America Believed to be Affected
    • 6.3.5 New Anti-Counterfeiting Security Measures as Part of the SNCM Due to Start in 2015 and Become Fully Operational in 2016
    • 6.3.6 Challenges for the Brazilian Generics Market
  • 6.4 Brazilian Biologics Market
    • 6.4.1 Biosimilars Market in Brazil to Double in Size by 2018
    • 6.4.2 BiocadBrazil Signs PDP for Bevacizumab and Intends to Bring More Biosimilars to Brazil
  • 6.5 OTC Segment Forecast 2015-2025
    • 6.5.1 OTC Segment: Analgesics, Multivitamins and Other Consumer Health Products Favoured by Brazilians
    • 6.5.2 Multivitamins Purchased by ~15% of Brazilians
    • 6.5.3 Coming Out From Behind the Counter
    • 6.5.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas in the Brazilian Market, 2015-2025

  • 7.1 Forecasts for CNS, Cardiovascular, Alimentary/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2025
  • 7.2 The Rise of Non-Communicable Diseases
  • 7.3 Market Forecast for CNS Conditions 2015-2025
    • 7.3.1 CNS Conditions: Currently the Largest Therapeutic Area in Brazil, Disease Burden Comparable to US
    • 7.3.2 Domestic Companies Target OTC and Generic CNS Treatments- Particularly in Pain Relief
    • 7.3.3 Foreign Competition in the Analgesics Field
    • 7.3.4 18.4% of Brazilians Have Suffered Depression in their Lives - Represents Major Opportunity in Antidepressant Space
    • 7.3.5 CNS Conditions: Drivers and Restraints
  • 7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2025
    • 7.4.1 Cardiovascular Diseases: Brazil's Biggest Killer
    • 7.4.2 Anti-hypertensives: One of the Nation's Key Drugs- as 23% of Brazilians Suffer from Hypertension
    • 7.4.3 Decline of the Statins
    • 7.4.4 Aché and Sanofi Among the Main Players in that Field
    • 7.4.5 Cardiovascular Opportunity and Challenges
  • 7.5 Forecast for Alimentary/Metabolic Therapeutic Area, 2015-2025
    • 7.5.1 Alimentary/Metabolic Diseases: Affecting More Than a Quarter of Brazilians
    • 7.5.2 Lack of Diabetes Awareness Still a Concern
    • 7.5.3 Brazil to Localise Insulin Production by 2016
    • 7.5.4 EMS' Generic Esomeprazole an Important Addition
    • 7.5.5 Capturing the Alimentary/Metabolic Disease Opportunity
  • 7.6 Market Forecast for Cancer Medicines, 2015-2025
    • 7.6.1 Cancer Treatment to Become the Biggest Therapeutic Area
    • 7.6.2 ANS Introduces Significant Changes to Cancer Care from Private Health Insurance Providers
    • 7.6.3 Most Common Cancers in Brazil, 2014
    • 7.6.4 Biosimilars to Help Widen Medicine Access
    • 7.6.5 Cristália, Libbs, Roche, Sanofi, Novartis and Amgen Among the Key Players in the Field
    • 7.6.6 Will the Oncology Therapeutic Area Realise its Potential?
  • 7.7 Forecast for Infectious Diseases Therapeutic Area, 2015-2025
    • 7.7.1 Infectious Diseases: Submarket Led by Vaccines and Antibiotics
    • 7.7.2 Vaccines- Brazil not just Reliant on Multinationals, but also Innovating in its own Right
    • 7.7.3 Brazil Managing HIV Despite IP Concerns
    • 7.7.4 Chagas Disease and Other Infections - the Challenge
    • 7.7.5 Infectious Disease: The Past for Brazilian Pharma?
  • 7.8 Other Therapeutic Areas

8. Domestic Companies in the Brazilian Market, 2015-2025

  • 8.1 The Top Ten Domestic Pharmaceutical Companies in Brazil, 2014
  • 8.2 Purchase of Medley in 2009 Means Multinationals Still Own Bulk of Market
  • 8.3 Domestic Firms Control 70% of Generics Market
  • 8.4 EMS: Brazil's Leading Pharmaceutical Company
    • 8.4.1 Company Split into Similar, OTC, Hospital, Generic and Prescription Divisions
    • 8.4.2 Full Production Capabilities and Significant R&D Capabilities
    • 8.4.3 Legrand and Germed Key Subsidiaries of EMS
    • 8.4.4 Targeting Expansion Oversees
  • 8.5 Hypermarcas: Market Leader in OTC and Branded Generics
    • 8.5.1 Neo Química: Ranked Third in the Generics Segment
    • 8.5.2 Subsidiaries include Mantecorp, Brainfarma, Cosmed, DM Industria Farmacêutica
  • 8.6 Medley: Foreign-Owned Generics Giant
  • 8.7 Aché: A Major Acquisition Target in Brazil
    • 8.7.1 Acheflan - the First Drug to be Developed in Brazil
    • 8.7.2 Possible M&A in the Near Future?
    • 8.7.3 A Large Domestic Merger an Alternative Possibility?
  • 8.8 Eurofarma: Fifth Largest Domestic Company, with Plans to Cover 90% of Latin America
    • 8.8.1 Relentless Latin American Acquisitions Policy
  • 8.9 Teuto: Largest Pharmaceutical Complex in Latin America
    • 8.9.1 Melcon Partnership and Other Growth Strategies for Teuto
  • 8.10 Biolab Farmacêutica: Leader in the Cardiology Prescription Drugs Market
    • 8.10.1 Joint Ventures with Merz and Emcure
    • 8.10.2 Number of New Product Launches in 2013 and Current Pipeline in 2015
  • 8.11 Cristalia: Largest Producer of Anaesthetics in Latin America
    • 8.11.1 Approval From ANVISA to Produce Biosimilar Drugs
    • 8.11.2 Leader in API Manufacturing
    • 8.11.3 Involved in a Third of All PDPs
  • 8.12 Libbs: Key Player in Cancer Treatment
    • 8.12.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
  • 8.13 União Química: Huge Annual Production Capacity
    • 8.13.1 Agreement with Novartis and Possible Public Offering in 2015
  • 8.14 Other Domestic Players Include Moksha8 and Laboratório Daudt Oliveira
  • 8.15 Biosimilar Collaborations
    • 8.15.1 Bionovis: Conglomerate Developing 8 Biosimilars and Aiming to Launch First Product in 2016
    • 8.15.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
  • 8.16 Other Biotech Players Include Biomm and Innova
  • 8.17 Fiocruz: At the Heart of Multiple PDPs
  • 8.18 ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market, 2015-2025

  • 9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2014
  • 9.2 Notable M&A Activity
  • 9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
    • 9.3.1 Group Companies Include Sanofi Pasteur and Genzyme - Overall Portfolio of Over 350 Products
    • 9.3.2 Inventory Mishandling and Dip in 2013 Results
  • 9.4 Novartis: Only Multinational to Produce APIs in Brazil
    • 9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
    • 9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
  • 9.5 Roche: No Regrets over Staying in Brazil
    • 9.5.1 Oncology Opportunity and Herceptin Pricing/Reimbursement
  • 9.6 Merck & Co. - Long-Standing Presence in the Brazilian Market
    • 9.6.1 Five Factories and Covers Five Broad Therapeutic Areas
    • 9.6.2 Gardasil Added to SUS in 2013
    • 9.6.3 Joint Venture with Eurofarma and Cristália
  • 9.7 Pfizer: Targeting Emerging Market Growth via M&A
    • 9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
  • 9.8 Takeda: Expanding its Brazilian Business Through Acquisitions and Aims to Launch New Drugs
    • 9.8.1 Acquisitions of Nycomed and Multilab and Global Restructuring
  • 9.9 Bayer: Brazil the Fifth-Largest Market for Diversified German Giant
    • 9.9.1 OTC a Major Focus in Brazil
  • 9.10 AstraZeneca Targets Latin America
    • 9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
  • 9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
    • 9.11.1 Looking to Acquire OTC Brands
    • 9.11.2 Technology Transfer Deal for Sifrol
  • 9.12 Merck KGaA : Present in Brazil since 1923; Signs PDP with Bionovis for 8 Biosimilars.
    • 9.12.1 Two Divisions and Multiple Therapeutic Fields
  • 9.13 Other Notable Multinationals in Brazil
    • 9.13.1 GlaxoSmithKline: Vaccines and Technology Transfer Opportunities
    • 9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
    • 9.13.2.1 Abbott: Generics and Diagnostics-Led Growth Strategy
    • 9.13.3 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
    • 9.13.4 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
    • 9.13.5 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer
    • 9.13.6 Johnson & Johnson: Focusing on Consumer Health and Commodities
    • 9.13.7 BiocadBrazil Farmaceutica
    • 9.13.8 Amgen Signals Brazilian Intent with Bergamo Acquisition
    • 9.13.9 Gilead, Novo Nordisk, Biogen, UCB and Meizler
    • 9.13.10 Other Top Japanese Companies Trail Behind Takeda in Brazil
  • 9.14 Will Multinational Generics Leaders Compete in Brazil?
    • 9.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil
    • 9.14.2 Mylan: Agila Acquisition Boosts Brazilian Strategy
    • 9.14.3 Actavis: Newly-Merged Player May Target Brazil
    • 9.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil
    • 9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
    • 9.14.6 Valeant: M&A Drive Into the Market
  • 9.15 Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2015-2025

  • 10.1 Strengths, Weaknesses, Opportunities, Threats within the Market, and Political, Social, Economic and Technological Factors
  • 10.2 A Crucial Market for the Pharmaceutical Industry
  • 10.3 Governmental Regulation Remains an Issue
  • 10.4 One of the Highest Pharmaceutical Tax Rates in the World
  • 10.5 Room to Expand in Therapeutic Areas and Geographical Regions
  • 10.6 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
  • 10.7 Large and Ageing Population Eager to Buy Medicines
  • 10.8 Improved Self-Sufficiency, Biotechnological and Digital, Among Government's Goals
  • 10.9 Economic Conditions in 2015 - Can Economic Growth Keep Pace With Healthcare Costs?
  • 10.10 Political Environment a Decisive Influence on the Market

11. Research Interview

  • 11.1 Interview with Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
  • 11.2 On Gaining Access to the Brazilian Market, Achieving Success and Factors That Differentiate Brazil from Other Markets
  • 11.3 The Brazilian Generics and Biosimilars Market, and Biocad's Progress on its Biosimilars for Brazil
  • 11.4 Biocad's Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
  • 11.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
  • 11.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market- and How the 2016 Olympics will Compare
  • 11.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses will Improve in Coming Years

12. Conclusions from the Research and Analysis

  • 12.1 Brazil Likely to Grow Faster than Most Other Top 10 Pharmaceutical Markets
  • 12.2 Generics to be the Fastest-Growing Segment
  • 12.3 Technology Transfer Crucial to Patented Drugs Market
  • 12.4 Generics: Opportunities for Multinationals?
  • 12.5 Cancer Treatment: Biggest Therapeutic and Commercial Opportunity
  • 12.6 Concluding Remarks

List of Tables

  • Table 1.1 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2013-2018
  • Table 1.2 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 1.3 Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2013-2018
  • Table 2.2 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2019-2025
  • Table 2.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
  • Table 2.4 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
  • Table 2.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
  • Table 3.1 World's Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
  • Table 3.2 Latin America's Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
  • Table 3.3 Pharmerging Markets
  • Table 4.1 Members of FenaSaúde (in Portuguese, with English in brackets), 2014
  • Table 6.1 Patented Prescription Drugs, Generics and OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
  • Table 6.2 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
  • Table 6.3 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
  • Table 6.4 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
  • Table 6.5 Prescription Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 6.6 Selected Technology Transfer Agreements in Brazil, 1985-2013
  • Table 6.7 Generic Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%). 2015-2025
  • Table 6.8 OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.1 Therapeutic Areas in the Brazilian Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
  • Table 7.2 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
  • Table 7.3 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
  • Table 7.4 CNS Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.5 Cardiovascular Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.6 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.7 Oncology Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.8 Infectious Diseases Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 7.9 Other Therapeutic Areas: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
  • Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
  • Table 8.2 EMS Overview, 2015
  • Table 8.3 Hypermarcas Overview, 2015
  • Table 8.4 Medley Overview, 2015
  • Table 8.5 Aché Overview, 2015
  • Table 8.6 Eurofarma Overview, 2015
  • Table 8.7 Teuto Overview, 2015
  • Table 8.8 Biolab Farmacêutica Overview, 2015
  • Table 8.9 Biolab Farmacêutica Pipeline, 2015
  • Table 8.10 Cristalia Overview, 2015
  • Table 8.11 Libbs Overview, 2015
  • Table 8.12 União Química Overview, 2015
  • Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
  • Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
  • Table 9.3 Sanofi Overview, 2015
  • Table 9.4 Novartis Overview, 2015
  • Table 9.5 Roche Overview, 2015
  • Table 9.6 Merck & Co Overview, 2015
  • Table 9.7 Pfizer Overview, 2015
  • Table 9.8 Takeda Overview, 2015
  • Table 9.9 Bayer Overview, 2015
  • Table 9.10 AstraZeneca Overview, 2015
  • Table 9.11 Boehringer Ingelheim Overview, 2015
  • Table 9.12 Merck KGaA Overview, 2015
  • Table 10.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2015
  • Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2015
  • Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2015

List of Figures

  • Figure 1.1 Product Segments Covered Within the Brazilian Pharmaceutical Market
  • Figure 1.2 Therapeutic Areas Covered Within the Brazilian Pharmaceutical Market
  • Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), 2013-2025
  • Figure 2.2 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
  • Figure 2.3 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
  • Figure 2.4 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
  • Figure 3.1 Top Ten Global Economies, 2013
  • Figure 3.2 Top Ten Global Economies, 2023
  • Figure 3.3 World's Largest Pharmaceutical Markets by Revenue Share, 2013
  • Figure 3.4 Latin America's Largest Pharmaceutical Markets by Revenue Share, 2013
  • Figure 3.5 BRIC Nations Pharmaceutical Market Revenues ($bn), 2013
  • Figure 4.1 Brazilian Public vs Private Healthcare, 2014
  • Figure 4.2 CMED-Mandated Average Price Rises, 2010-2014
  • Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013
  • Figure 5.2 Brazil: Regional Population Shares (%), 2012
  • Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012
  • Figure 5.4 Brazilian GDP Shares (%) by Region, 2012
  • Figure 6.1 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
  • Figure 6.2 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
  • Figure 6.3 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
  • Figure 6.4 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013, 2018, 2025
  • Figure 6.5 Patented Prescription Drugs Segment Revenue ($bn), 2013-2025
  • Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2015
  • Figure 6.7 Generic Drugs Segment Revenue ($bn), 2013-2025
  • Figure 6.8 Drivers and Restraints for Generic Drugs, 2015
  • Figure 6.9 Brazilian Biologics Market Breakdown: Revenues ($bn) and Market Shares (%), 2013
  • Figure 6.10 Brazilian Biologics Market Breakdown: Revenues ($bn), 2013, 2019, 2025
  • Figure 6.11 OTC Drugs Segment Revenue ($bn), 2013-2025
  • Figure 6.12 Drivers and Restraints for OTC Drugs, 2015
  • Figure 7.1 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
  • Figure 7.2 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
  • Figure 7.3 Therapeutic Area Breakdown: Revenues ($bn), 2013-2025
  • Figure 7.4 Therapeutic Area Breakdown: Revenues ($bn), 2013, 2018, 2025
  • Figure 7.5 CNS Therapeutic Area: Revenues ($bn) 2013-2025
  • Figure 7.6 Drivers and Restraints for CNS Conditions, 2015
  • Figure 7.7 Cardiovascular Therapeutic Area: Revenues ($bn), 2013-2025
  • Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2015
  • Figure 7.9 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), 2013-2025
  • Figure 7.10 Drivers and Restraints for the Alimentary/Metabolic Therapy Area, 2015
  • Figure 7.11 Oncology Therapeutic Area: Revenues ($bn), 2013-2025
  • Figure 7.12 Cancer Incidence in Males in Brazil: Numbers of Cases, 2014
  • Figure 7.13 Cancer Incidence in Males in Brazil: Shares (%), 2014
  • Figure 7.14 Cancer Incidence in Females in Brazil: Numbers of Cases, 2014
  • Figure 7.15 Cancer Incidence in Females in Brazil: Shares (%), 2014
  • Figure 7.16 Drivers and Restraints for the Oncology Therapeutic Area, 2015
  • Figure 7.17 Infectious Diseases Therapeutic Area: Revenues ($bn), 2013-2025
  • Figure 7.18 Drivers and Restraints for the Infectious Disease Therapeutic Area, 2015
  • Figure 7.19 Other Therapeutic Areas: Revenue ($bn), 2013-2025
  • Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
  • Figure 8.2 Ache Product Portfolio Breakdown (%), 2013
  • Figure 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
  • Figure 12.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2013-2018
  • Figure 12.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2019-2025
  • Figure 12.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2018
  • Figure 12.4 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2019-2025
  • Figure 12.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), 2014
  • Figure 12.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2013-2018
  • Figure 12.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2019-2025

Companies Listed

  • Abbott
  • Abbvie
  • ABRAFARMA (Associação Brasileira das Redes de Farmácias e Drogarias)
  • Aché
  • Actavis
  • Agila Specialties
  • Allianz Saúde
  • Alteogen
  • American Diabetes Association
  • AmerisourceBergen Corporation
  • Amgen
  • Amil Participações
  • ANS (Agência Nacional de Saúde Suplementar)
  • Antaris Consulting
  • ANVISA
  • Arcolab
  • Arena Pharmaceuticals
  • Associação Brasileira de Reabilitação de Coluna
  • Associação Nacional de Assistencia ao Diabetico
  • Astellas
  • AstraZeneca
  • Athos Farma
  • Axis Biotec
  • Baxter
  • Bayer
  • Bergamo
  • Bill & Melinda Gates Foundation
  • Biocad
  • BiocadBrazil Farmaceutica
  • Biocon
  • Biogen
  • Biolab Emcure
  • Biolab Farmacêutica
  • Biomanguinhos
  • Biomm
  • Bionovis
  • Biosintética
  • BNDES (The Brazilian National Bank for Economic and Social Development)
  • Boehringer Ingelheim
  • Boiron
  • Brainfarma Industria e Farmaceutica
  • Brasil Pharma
  • Brazilian Medical Association
  • Bristol-Myers Squibb
  • BTG Pactual
  • Bunker Industria Farmaceutica
  • Butantan Institute
  • Care Plus Medicina Assistencial
  • CEBR (Centre for Economics and Business Research)
  • Ceitec
  • Celesio
  • Chemo
  • Claris Lifesciences
  • CMED (Câmara de Regulação do Mercado de Medicamentos)
  • Corporacion Infarmasa
  • Cosmed Industria de Cosmeticos e Medicamentos
  • Cristália
  • CVS Pharmacy
  • Daiichi Sankyo
  • Dimed
  • DM Industria Farmaceutica
  • DPSP SA
  • Eli Lilly
  • Emcure
  • Empresas Andromaco
  • EMS
  • Eurofarma
  • Everis
  • Farmácia Popular
  • Farmais
  • Farmalife
  • Farmanguinhos
  • FDA (US Food and Drug Administration)
  • Federal Council of Medicine
  • FenaSaúde
  • Fiocruz
  • Forest Laboratories
  • FUNED (Fundação Ezequiel Dias)
  • Gama Saúde
  • Germed Pharma
  • Gilead
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Golden Cross
  • Grunenthal
  • Grupo Amil Saúde
  • Grupo Bradesco Saúde
  • Grupo Caixa Seguros Saúde
  • Grupo Cimed
  • Grupo Intermédica
  • Grupo SulAmérica Saúde
  • Grupo Tempo Saúde
  • GTPI (The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples)
  • Hapvida Assistência Médica
  • Health Canada
  • Hebron
  • Hemobras
  • Horizon Pharma
  • Hospital das Clínicas
  • Hospital Israelita Albert Einstein
  • Hospital Santa Catarina
  • Hypermarcas
  • IESS (Instituto de Estudos de Saúde Suplementar)
  • IMA Laboratories
  • Indar Institute
  • Indian Council of Medical Research
  • Innova
  • INSS (The Brazilian National Institute of Social Security)
  • Instituto Terapeutico Delta
  • Instituto Vital Brazil
  • InterFarma
  • Itauseg Saúde
  • Johnson & Johnson
  • Kantar Health
  • Kenya Medical Research Institute
  • Laboratório Daudt Oliveira
  • Laboratórios Klinger Do Brasil
  • LAFEPE (Laboratório Farmacêutico do Estado de Pernambuco)
  • Laprin
  • Lazard
  • Legrand
  • Libbs
  • Libbs Biotec
  • Luper Indústria Farmacêutica
  • mAbxience
  • Malaysian Ministry of Health
  • Mantecorp Industria Quimica e Farmaceutica
  • Marítima Saúde Seguros
  • Medley
  • Meizler Biopharma
  • Merck & Co.
  • Merck KGaA
  • Merz
  • Metlife Exclusivamente Odontológicos
  • Minas Gerais State Department of Health
  • Ministry of Health
  • Moksha8
  • MSF (Médecins sans Frontières)
  • Multilab Industria e Comercio de Productos Farma
  • Mundipharma
  • Mylan
  • Nature's Plus Farmacêutica
  • NeoQuimica
  • Novartis
  • Novo Nordisk
  • Nycomed
  • Odontoprev
  • Omint Serviços de Saúde
  • Oncoprod
  • Orygen
  • Otsuka
  • Pan American Health Organisation
  • Panarello
  • Panpharma
  • Pasteur Institute of France
  • Pele Nova
  • Pfizer
  • PharmaPraxis
  • Piramal
  • Porto Seguro - Seguro Saúde
  • Probiomed
  • Probiotica
  • Profarma
  • Profarma Speciality
  • Pró-Genéricos
  • Protalix Biotherapeutics
  • Quesada Farmacêutica
  • Quintiles
  • Raia Drogasil
  • Ranbaxy
  • Reckitt Benckiser
  • Roche
  • Sandoz do Brasil Indústria Farmacêutica
  • Sanobiol
  • Sanofi
  • Shasun Pharma
  • Sincamesp
  • Sinclair IS Pharma
  • Sistema único de Saúde (SUS)
  • Sindusfarma
  • Sun
  • Supera Farma Laboratorios
  • Takeda
  • Tamoio
  • Tecpar
  • Telefônica Digital
  • Teuto
  • Teva Pharmaceutical Industries
  • The Sabin Vaccine Institute
  • The World Bank
  • TKS Farmacêutica
  • Torrent
  • UCB (Union Chimique Belge)
  • UERJ (Universidade do Estado do Rio de Janeiro)
  • União Química
  • UNICAMP (Universidade Estadual de Campinas)
  • Unimed Seguros Saúde
  • University of São Paulo
  • Valeant
  • Walgreens
  • Warc
  • Watson
  • WHO (World Health Organization)
  • Wockhardt
  • Zydus Cadila
Back to Top